Keywords: Alopecia areata; quality of life; DLQI;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Ab; antibody; DLQI; dermatology quality of life index; LCN2; lipocalin 2; NGAL; neutrophil gelatinase-associated lipocalin; PBMC; peripheral blood mononuclear cells; PPP; palmoplantar pustular psoriasis; PV; psoriasis vulgaris; Skin inflammation; Biomarke
Keywords: fixed combination; halobetasol; psoriasis; tazarotene; topical; AE; adverse event; BSA; body surface area; DLQI; Dermatology Life Quality Index; HP/TAZ; halobetasol propionate 0.01% plus tazarotene 0.045%; IGA; Investigator's Global Assessment; QoL; quali
Keywords: Urticaria; Guidelines; Antihistamines; Omalizumab; Cyclosporine; anti-H1; H1 antihistamines; CSU; Chronic spontaneous urticaria; DLQI; Dermatology Life Quality Index; EAACI; European Academy of Allergy and Clinical Immunology; UAS; Urticaria Activity Scor
Keywords: AD; atopic dermatitis; DLQI; dermatology life quality index; EASI; eczema area and severity index; IFN; interferon; IL; interleukin; KFDA; korea food and drug administration; SCORAD; SCORing AD; TEWL; transepidermal water loss; Atopic dermatitis; Topical
Keywords: AD; atopic dermatitis; DLQI; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; IQR; interquartile range; NRS; numeric rating scale; oSCORAD; objective component of the Scoring Atopic Dermatitis index; POEM; Patient-Oriented Eczema Meas
Keywords: VAS; visual analogue scale; SCORAD; SCORing Atopic Dermatitis; EASI; Eczema Area and Severity Index; POEM; Patient Oriented Eczema Measure; DLQI; Dermatology Life Quality Index; BIS; baseline index score; STRICTA; STandards for Reporting Interventions in
Keywords: 4 years; interleukin 17; ixekizumab; long-term; open-label; psoriasis; BCC; basal cell carcinoma; DLQI; Dermatology Life Quality Index; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IL; interleukin; LOCF; last observation c
Keywords: Chronic pruritus; Itch instruments; Measurement of itch; Numeric rating scale; Psychometric; BDI; Beck Depression Inventory; DLQI; Dermatological Life Quality Index; DPS; Dynamic Pruritus Score; EADV; European Academy of Dermatology and Venereology; HADS;
Keywords: discontinuation; methotrexate; moderate-to-severe psoriasis; Psoriasis Area and Severity Index (PASI); prediction; response; AUC; area under the curve; DLQI; Dermatology Life Quality Index; ITT; intent-to-treat; PASI; Psoriasis Area and Severity Index; PA
Keywords: psoriasis; psychodermatology; quality of life; skin lesions; social rejection; social stigma; stigmatization; DLQI; Dermatology Life Quality Index; FSQ; Feelings of Stigmatization Questionnaire; HRQoL; health-related quality of life; PASI; Psoriasis Area
Keywords: burden; DLQI; EQ-5D VAS; hidradenitis suppurativa; psoriasis; quality of life; SF-36; TWPI; VAS-pain; DLQI; Dermatology Life Quality Index; EQ-5D; EuroQOL 5D; HRQoL; health-related quality of life; HS; hidradenitis suppurativa; MCS; mental component score
Keywords: AD; atopic dermatitis; CAMs; complementary and alternative medicines; TNF-α; tumor necrosis factor-α; IFN-γ; interferon gamma; IL; interleukins; TGF-β1t; issue growth factor-β1; IgE; immunoglobulin-E; IgG; immunoglobulin-G; GOT; glutamic oxaloacetic
Keywords: Acitretin (PubChem CID:5284513); Methotrexate (PubChem CID:126941); DLQI; dermatology life quality index; ELISA; enzyme linked immunosorbent assay; IL; interleukin; PASI; psoriasis area and severity index; qRT-PCR; quantitative real-time polymerase chain
Keywords: CI; confidence interval; DLQI; dermatology life quality index; NMA; network meta-analysis; PASI; psoriasis area and severity index; RCT; randomized controlled trial; SUCRA; surface under the cumulative ranking curve;
Keywords: biological therapy; psoriasis; ustekinumab; ADA; antidrug antibodies; DLQI; Dermatology Life Quality Index; PASI; Psoriasis Area and Severity Index;
Keywords: cohort; corticosteroid; pyoderma gangrenosum; side effects; tacrolimus; topical therapy; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQol 5 dimensions, 3 levels; PG; pyoderma gangrenosum; RCT; randomized controlled trial; TNF; tumor necrosis factor
Keywords: AD; atopic dermatitis; BSA; body surface area; CDLQI; Children's Dermatology Life Quality Index; DFI; Dermatitis Family Impact; DLQI; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; HOME; Harmonising Outcome Measures for Eczema; IDQO
Keywords: Dermatology Life Quality Index; health-related quality of life; patient-reported outcomes; plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis Symptom Inventory; static Physician Global Assessment; DLQI; Dermatology Life Quality Index; HRQoL; h
Keywords: Omalizumab; Urticaria; Chronic spontaneous; Chronic idiopathic; Itch; Hive; Pruritus; Wheal; Antihistamine; AE; Adverse event; CI; Confidence interval; CIU; Chronic idiopathic urticaria; CSU; Chronic spontaneous urticaria; CU; Chronic urticaria; DLQI; Der
Keywords: cohabitants; DLQI; FDLQI; HADS; psoriasis; quality of life; secondary impact;
Keywords: Psoriasis; Inflammation; Obesity; n-3 Polyunsaturated fatty acids; n-6 Polyunsaturated fatty acids; Diet therapy; AA; arachidonic acid; AHA; American Heart Association; ALA; alpha-linolenic acid; DGLA; dihomo-gamma-linolenic acid; DHA; docosahexaenoic aci
Keywords: depression; dermatology; mental health; psychosocial; quality of life; rosacea; self-esteem; self-image; DLQI; Dermatology Life Quality Index; QoL; quality of life; SF; Short Form; WTP; willingness to pay;
Keywords: Dermatology Life Quality Index; patient-reported outcome; Physician Global Assessment; psoriasis; Psoriasis Area and Severity Index; quality of life; BSA; body surface area; CI; confidence interval; DLQI; Dermatology Life Quality Index; HRQoL; health-rela
Keywords: biologics; combination therapy; comparative effectiveness; Dermatology Life Quality Index; Physician Global Assessment; psoriasis; quality of life; systemic treatments; BSA; body surface area; DLQI; Dermatology Life Quality Index; FDA; Food and Drug Admin
Keywords: Psoriasis; Comorbilidades; Criterios de gravedad: BSA; Body Surface Area; PASI; Psoriasis Area and Severity Index; DLQI; Dermatology Life Quality Index; Fototerapia; Retinoides; Metotrexato; Ciclosporina; Terapia biológica;
Keywords: chronic urticaria; diet; melanoma; nutrition; psoriasis; DLQI; Dermatology Life Quality Index; EGCG; epigallocatechin-3-gallate; IgE; immunoglobulin E; PASI; Psoriasis Area and Severity Index; PUFA; polyunsaturated omega-3 fatty acid; RCT; randomized, con
Keywords: health survey; patient satisfaction; psoriasis; psoriatic arthritis; quality of life; questionnaires; BSA; body surface area; DLQI; Dermatology Life Quality Index; HAQ-8; 8-item Health Assessment Questionnaire; HCP; health care provider; MAPP; Multination
Keywords: Chronic idiopathic urticaria; chronic spontaneous urticaria; H1-antihistamine; H2-antihistamines; hive; itch; leukotriene receptor antagonist; omalizumab; pruritus; wheal; AE; Adverse event; CIU/CSU; Chronic idiopathic urticaria/chronic spontaneous urtica
Keywords: Alopecia areata; Androgenetic alopecia; Disorders; DLQI; Illness perception; Psychological
Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis
Keywords: dermatology; DLQI; EQ-5D; mapping; psoriasis; utility;
Dupilumab: A review of its use in the treatment of atopic dermatitis
Keywords: biologics; dupilumab; IL-4; IL-13; IL-4Rα; moderate-to-severe atopic dermatitis; systemic therapy; AD; atopic dermatitis; ADA; antidrug antibody; CCL; C-C motif chemokine ligand; CYP450; cytochrome P450; DLQI; Dermatology Life Quality Index; EASI; Eczema
Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial
Keywords: Atopic dermatitis; Methotrexate; Cyclosporine; Trial; DLQI; Dermatology Life Quality Index (score ranging from 0 to 30, a higher score indicating a greater severity); EASI index; Eczema Area Severity Intensity index (score ranging from 0 to 72, a higher s
Epidermal barrier and oxidative stress parameters improve during in 311â¯nm narrow band UVB phototherapy of plaque type psoriasis
Keywords: Asc; ascorbyl radicals; CAT; catalase; EDTA; ethylenediaminetetraactete; EPR; Electron Paramagnetic Resonance; MDA; malondialdehyde; DLQI; dermatology life quality index; NB-UVB; 311â¯nm narrow band ultraviolet B; PASI; psoriasis area and severity index;
Omalizumab treatment in patients with chronic inducible urticaria: AÂ systematic review of published evidence
Keywords: IgE; physical urticaria; therapy; symptomatic dermographism; cholinergic urticaria; AE; Adverse event; CIndU; Chronic inducible urticaria; CSU; Chronic spontaneous urticaria; CU; Chronic urticaria; DLQI; Dermatology Life Quality Index; QoL; Quality of lif
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Keywords: cumulative benefit; itching; pain; psoriasis; quality of life; scaling; secukinumab; AUC; area under the curve; CI; confidence interval; DLQI; Dermatology Life Quality Index; HRQoL; health-related quality of life; MCID; minimal clinically important differ
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Keywords: biologic therapy; effectiveness; psoriasis; real-world; registry; safety; systemic therapy; BSA; body surface area; BMI; body mass index; DLQI; Dermatology Life Quality Index; EQ-5D; Euro-QoL-5 Dimensional; EQ-5D-3L; Euro-QoL-5 Dimensional-3 Level; IGA; I
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Keywords: anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPASI-1; CIMPASI-2; phase 3 trial; CZP; certolizumab pegol; DLQI; Dermatology Life Quality Index; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index;
Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
Keywords: chronic pruritus; itch; neurokinin 1 receptor; NK1 receptor; NK1 receptor antagonist; serlopitant; substance P; DLQI; Dermatology Life Quality Index; e-diary; electronic diary; NK1R; neurokinin 1 receptor; NRS; numeric rating scale; PGA; Physician's Globa
Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630Â nm laser beam
Keywords: HS; Hidradenitis suppurativa; I-PDT; Intralesional photodynamic therapy; HSS; Hidradenitis Severity Score; DLQI; Dermatology Life Quality Index; ALA; aminolevulinic acid; W; Watt; OR; Odds ratios; CI; confidence intervals; IR; interquartile range; H âL;
Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria
Keywords: AE; adverse event; ANCOVA; analysis of covariance; BMI; body mass index; BOCF; baseline-observation-carried-forward; CIU; chronic idiopathic urticaria; CSU; chronic spontaneous urticaria; DLQI; Dermatology Life Quality Index; EAACI; European Academy of Al
Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study
Keywords: Bilastine; Chronic spontaneous urticaria; DLQI; H1-antihistamine; Total symptom score; ANCOVA; analysis of covariance; CI; confidence interval; CSU; chronic spontaneous urticaria; DLQI; Dermatology Life Quality Index; FAS; full analysis set; QOL; quality
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Keywords: palmoplantar psoriasis; clear or almost clear skin; clinical trial; secukinumab; superiority; quality of life; AE; adverse event; BSA; body surface area; DLQI; Dermatology Life Quality Index; EQ-5D; Euro Quality-of-Life 5-Dimension Health Status Questionn
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-
Keywords: adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; f-PGA; Fingernail Physician Global Assessment; HRQoL; health-relate
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, p
Keywords: adalimumab; efficacy; guselkumab; interleukin-23; psoriasis; safety; switching; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; IGA; Investigator Global Assessment; IL; interleukin; ISR; injection site reaction; MACE; major ad
Surgery combined with photodynamic therapy for the treatment of Hidradenitis Suppurativa: A report of 7 cases
Keywords: HS; Hidradenitis Suppurativa; PDT; photodynamic therapy; ALA; 5-aminolevulinic acid; DLQI; dermatology life quality ondex; VSS; vancouver scar scale; Surgery; Photodynamic therapy; Hidradenitis suppurativa; Wound healing; Scar;
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Â year: Results from the CLEAR study
Keywords: psoriasis; secukinumab; ustekinumab; clinical trial; Psoriasis Area and Severity Index (PASI); efficacy; safety; AE; adverse event; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQoL 5-Dimension Health Questionnaire 3-level version; HAQ-DI; Health As
Efficacy and safety of canakinumab in Schnitzler syndrome: AÂ multicenter randomized placebo-controlled study
Keywords: Autoinflammatory; canakinumab; IL-1; Schnitzler syndrome; urticaria; CAPS; Cryopyrin-associated periodic syndrome; CRP; C-reactive protein; DLQI; Dermatology Life Quality Index; IL-1Ra; IL-1 receptor antagonist; PGA; Physician global assessment; SAA; Seru
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
Keywords: atopic dermatitis; atopic eczema; OPA-15406; phosphodiesterase type 4 inhibitor; topical agents; topical calcineurin inhibitor; AD; atopic dermatitis; BSA; body surface area; DLQI; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; IGA;
ReviewSystematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent
Keywords: adalimumab; etanercept; failure; infliximab; psoriasis; switching; tumor necrosis factor antagonist; DLQI; Dermatology Life Quality Index; PASI; Psoriasis Area and Severity Index; PASI50; 50% improvement in Psoriasis Area and Severity Index score; PASI75;